Table 1 Baseline Characteristics of the Two Cohorts
From: Retrospective study assessing outcomes in cardiac surgery after implementation of Quantra
Pre-Quantra | Post-Quantra | P-Value | |||
|---|---|---|---|---|---|
N | 64 | 64 | |||
Women (n, %) | 19 | 29.69% | 19 | 29.23% | 0.9522 |
Age (mean, SD) | 71.59 | 8.46 | 70.55 | 9.13 | 0.4279 |
Hypertension (n, %) | 35 | 54.69% | 49 | 76.56% | 0.0155* |
Diabetes (n, %) | 13 | 20.31% | 17 | 26.56% | 0.5313 |
COPD (n, %) | 6 | 9.38% | 5 | 7.81% | > 0.999 |
Kidney disease (n, %) | 2 | 3.13% | 9 | 14.06% | 0.0585 |
Dyslipidemia (n, %) | 20 | 31.25% | 13 | 20.31% | 0.2254 |
Anemia (n, %) | 1 | 1.56% | 3 | 4.69% | 0.6115 |
Platelets (x1000/uL) (mean, SD) | 197.53 | 53.70 | 210.20 | 51.53 | 0.5602 |
INR (mean, SD) | 1.12 | 0.11 | 1.09 | 0.17 | 0.2661 |
aPTT (s) (mean, SD) | 32.35 | 7.22 | 35.64 | 16.00 | 0.1476 |
Hemoglobin (g/L) | 13.94 | 2.29 | 14.15 | 1.88 | 0.5904 |
Hematocrit (%) (mean, SD) | 42.31 | 6.40 | 42.61 | 5.56 | 0.7820 |
Prehospital Medications1 | |||||
Aspirin (n, %) | 12 | 18.75% | 16 | 24.62% | 0.4179 |
Clopidogrel (n, %) | 1 | 1.56% | 1 | 1.56% | 0.9920 |
Phytonadione (n, %) | 1 | 1.56% | 0 | 0.0% | 0.3125 |
LMWH (n, %) | 11 | 17.19% | 16 | 24.62% | 0.2983 |